A reshuffle at Daiichi Sankyo and appointments at Fate Therapeutics and 3-V Biosciences – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Daiichi sankyo Pharmacology Medicine

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a reshuffle at Daiichi Sankyo and appointments at Fate Therapeutics and 3-V Biosciences.

Daiichi Sankyo​ has proposed that Joji Nakayama ​take the positions of president and CEO. Current CEO Takashi Shoda ​is due to take the role of chairman, with Kiyoshi Morita ​in-line to become corporate advisor.

Also, Nakayama​, Kazunori Hirokawa​, Hiroshi Hirabayashi​, Ikuo Ishihara​ and Yuichiro Anzai​ have been selected as prospective board candidates.

Lee Rauch ​has been appointed as CEO of Nuon Therapeutics​. Rauch has previously worked at Point Biomedical, Onyx, COR Therapeutics and Syntex.

Fate Therapeutics ​has named Tom Novak ​as vice president (VP) of research and drug discovery. Novak most recently worked at Roche and has also held positions at Wyeth.

Stephen Brady ​has been hired as VP, corporate development, strategy and operations at 3-V Biosciences​. Earlier in his career Brady worked at Proteolix, Lexicon Pharmaceuticals and Lazard Venture Advisors.

3-V ​has also promoted to Robert McDowell​ to the position of VP, research. McDowell joined 3-V in 2008 and has also worked at Sunesis, Genentech and Axys Pharmaceuticals.

Mikel Moyer ​has been named as VP of molecular discovery at Epizyme​. Moyer joins from the Broad Institute and also worked at Pfizer for 18 years.

Cobalis ​has appointed Martin Marion ​as CEO. Marion has previously worked at Grey Advertising / Grey Direct and Medicus.

Related topics Markets & Regulations

Related news

Show more

Follow us


View more